Q3 2022
Quarter Ended Sep 30, 2022
Form 8937
VIEW PDFLatest Financial Results
Latest 10-K
Financials
View the latest financials
Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances
For more details, click here for the full news release.